Biogen Q2 2024 Adj. EPS $5.28 Beats $4.03 Estimate, Sales $2.465B Beat $2.382B Estimate
Portfolio Pulse from Benzinga Newsdesk
Biogen reported its Q2 2024 results, with adjusted EPS of $5.28 beating the estimate of $4.03, and sales of $2.465 billion surpassing the expected $2.382 billion.
August 01, 2024 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's Q2 2024 adjusted EPS of $5.28 beat the estimate of $4.03, and sales of $2.465 billion surpassed the expected $2.382 billion. This strong performance is likely to positively impact the stock price in the short term.
Biogen's better-than-expected earnings and revenue figures indicate strong financial performance, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100